Abstract:Lung cancer is a lethal disease, and early diagnosis with the aid of biomarkers such as HSP90α protein can certainly assist the doctors to start treatment of patient at the earliest and can save their lives. To analyse the diagnostic value of HSP90α expression in lung cancer patients by collecting data of patients through IoT devices to avoid delay in treatments, a study has been presented in this paper where the significance of HSP90α biomarker is highlighted in early diagnosis of patients suffering from lung cancer. The second objective of the research study is to examine the correlation between the appearance level of HSP90α biomarker and the clinicopathological features of lung cancer. It is also evaluated whether the changes in HSP90α index are indicative or noteworthy before and after surgery of lung cancer patients. An observatory study of 78 patients with lung cancer in Qinhuangdao Hospital is presented in this paper where the samples were collected from June 2018 to March 2020. Their data were collected through IoT devices used in the latest healthcare facilities of the hospital. The ELISA method was utilized to identify the level of plasma HSP90 and to analyse HSP90 levels between the lung cancer group and healthy group of people. The relationship between HSP90 and the clinical pathological features of 78 patients suffering from lung cancer was analysed. An electrochemical luminescence method was used to detect CEA, NSE, SCC, and CYFRA21-1 levels. ROC curve and box plots were used to determine the analytic value of HSP90 and other biomarkers used in lung cancer diagnosis. Forty-two patients with moderate to early stage lung cancer with surgical correction were selected, and paired sample T test was used to analyse HSP90 levels before and after surgery. The plasma HSP90 level of lung cancer patients was quite higher as compared to the group of healthy people as per the values depicted in the research study. Second, HSP90 levels are substantially higher in pathologic type, differentiation degree, stage, and the existence of the lung, liver, and bone metastases (P < 0.05). The level of HSP90 expression was largely impacted by a few factors such as sex, age, smoking, and tumour location (P > 0.05). The ROC value for HSP90 was 0.599, while the area under the curve of HSP90 combined with other four tumour markers was 0.915 in the presented case study, indicating the presence of lung cancer. Patients with lung cancer had statistically significant differences in HSP90 expression levels before and after surgery (P < 0.05). It is concluded that the expression level of plasma HSP90α in lung cancer patients increases remarkably; therefore, HSP90 can be used to monitor presence of lung cancer before and after surgery in the patients.

Extracellular Hsp90 Promotes Tumor Lymphangiogenesis and Lymph Node Metastasis in Breast Cancer

Plasma heat shock protein 90 alpha in the diagnosis and treatment of breast cancer

Extracellular Hsp90α and Clusterin Synergistically Promote Breast Cancer Epithelial-to-mesenchymal Transition and Metastasis Via LRP1.

HSP90AA1 promotes lymphatic metastasis of hypopharyngeal squamous cell carcinoma by regulating epithelial-mesenchymal transition

Plasma HSP90AA1 Predicts the Risk of Breast Cancer Onset and Distant Metastasis

Plasma Heat Shock Protein 90alpha As a Biomarker for the Diagnosis of Liver Cancer: an Official, Large-scale, and Multicenter Clinical Trial.

Plasma Levels of Heat Shock Protein 90 Alpha Associated With Colorectal Cancer Development

Extracellular heat shock protein 90 alpha (eHsp90α)'s role in cancer progression and the development of therapeutic strategies

A Novel Pan‐cancer Biomarker Plasma Heat Shock Protein 90alpha and Its Diagnosis Determinants in Clinic

The effects of Hsp90 expression alteration on spinal metastases of breast carcinoma

Identification of HSP90B1 in pan-cancer hallmarks to aid development of a potential therapeutic target

Hsp90 Inhibitor STA9090 Induced VPS35 Related Extracellular Vesicle Release and Metastasis in Hepatocellular Carcinoma

Extracellular Hsp90α Supports the ePKM2-GRP78-AKT Axis to Promote Tumor Metastasis

Secreted HSP90α-LRP1 Signaling Promotes Tumor Metastasis and Chemoresistance in Pancreatic Cancer

Diagnostic value of plasma HSP90α levels for detection of hepatocellular carcinoma

Plasma Hsp90 Level as a Marker of Early Acute Lymphoblastic Leukemia Engraftment and Progression in Mice

Impact of HSP90 α, CEA, NSE, SCC, and CYFRA21-1 on Lung Cancer Patients

The Regulatory Mechanism Of Hsp90 Alpha Secretion And Its Function In Tumor Malignancy

Diagnostic value of HSP90α and Related Markers in Lung Cancer

Evaluation of plasma LC3B+extracellular vesicles as a potential novel diagnostic marker for hepatocellular carcinoma

HspA1B Is a Prognostic Biomarker and Correlated With Immune Infiltrates in different subtypes of Breast Cancers